A panel of experts at the US Food and Drug Administration has recommended Merck & Co's insomnia drug suvorexant when given in lower dosages but rejected the higher dose that the company was seeking ...more World News
Top companies and individuals recognised for improving the life sciences skills base
...more UK News
UK-based contract research organisation ClinTec International will formally open an office in Istanbul, Turkey as the company further consolidates its strong presence in the Middle East and North Africa (MENA) region.
...more Clinical News
A panel of experts at the US Food and Drug Administration has recommended Merck & Co's insomnia drug suvorexant when given in lower dosages but rejected the higher dose that the company was seeking
As Ranbaxy laid out some of the actions it has taken "to address certain conduct of the past" to ensure the safety of its products, reports are circulating that the Indian drugmaker could shed up to a third of its salesforce
GlaxoSmithKline has entered into a deal with the US government to develop drugs to fight antibiotic resistance and bioterrorism
Pfizer has announced plans to wind down its interest in animal health group Zoetis in order to focus on its core biopharmaceuticals business.
Boehringer Ingelheim says it will act promptly to resolve a series of manufacturing complaints highlighted by regulators in the USA concerning violations at its German headquarters
In 2006-07, the NHS in England spent £5.6 billion on care provided by non-NHS providers, but by 2011-12 this figure had soared to £8.7 billion, according to new research.
15 Academic Health Science Networks licensed to operate in England
A first-in-class treatment for irritable bowel syndrome (IBS) has been launched in the UK this week, offering patients a new option that, for the first time, addresses a variety of symptoms caused by the condition.
The US-based Association of Clinical Research Organizations (ACRO) has joined national grouping the Coalition of Small Business Innovators, citing the need to ensure funding for emerging research-intensive companies in the biopharmaceutical and medical device sectors.
While race and gender are often mentioned as factors complicating efforts to ensure clinical trials are conducted in representative populations, new research suggests that similar distinctions may apply to the personnel managing a clinical study.
Geoff Frew, Managing Editor
